Navigation Links
EntreMed Announces Changes to Board of Directors and CEO Appointment
Date:4/5/2013

of every committee of the Board.  We sincerely wish Mark all the best in the future and thank him very much for his service to our Company."

EntreMed further announced that Ken K. Ren , Ph.D. has been appointed Chief Executive Officer, after having completed his one-year term as interim CEO.  Dr. He stated, "Over the past year, Ken has been instrumental in developing and executing the Company's strategy and has demonstrated executive leadership and navigated development of our ENMD-2076 program to create value for our shareholders.  We are thrilled that Ken will continue to lead the Company into a promising future."

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company employing a drug development strategy primarily in the United States and China to develop targeted therapeutics for the global market.  Its lead compound, ENMD-2076, a selective angiogenic kinase inhibitor, has completed several Phase 1 studies in solid tumors, multiple myeloma, and leukemia, and is currently completing a multi-center Phase 2 study in ovarian cancer.  EntreMed, Inc. recently announced the initiation of a Phase 2 study of ENMD-2076 in triple-negative breast cancer and the initiation of a Phase 2 study of ENMD-2076 in advanced/metastatic soft tissue sarcoma.  Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission (the SEC).

About ENMD-2076

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action.  ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase.  Aurora kinases are key regulators of mitosis (cell division), and are often over-expres
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. EntreMed Reports Fourth Quarter And Year-End 2012 Financial Results And Business Outlook For 2013
2. EntreMed To Raise $10.7 Million In Registered Direct Offering
3. EntreMed Announces Initiation Of Phase 2 Trial In Advanced/Metastatic Soft Tissue Sarcoma
4. PNAS Publishes Preclinical Results of EntreMeds 2ME2 for Multiple Sclerosis
5. EntreMed Announces Publication Of Preclinical Results For ENMD-2076 In Triple-negative Breast Cancer
6. Dana-Farber Cancer Institutes Ursula A. Matulonis, MD Article on EntreMeds ENMD-2076 Published in the European Journal of Cancer
7. EntreMed Reports Second Quarter 2012 Financial Results
8. EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer
9. EntreMed Reports First Quarter 2012 Financial Results
10. AstraZeneca Announces Top-Line Results From OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis
11. Zimmer Holdings Announces Live Audio Webcast and Conference Call of First Quarter 2013 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients ... to a recent online survey* sponsored by Mission Pharmacal ... the National Osteoporosis Foundation online support community, revealed that ... medication that comes in a form other than a ...
(Date:1/15/2014)... N.J. , Jan. 15, 2014  Celsion Corporation (the "Company") ... has received commitments from institutional investors to purchase an ... stock in an at-the-market registered direct offering, led by ... entered into definitive purchase agreements with these investors pursuant ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that ... BioMarin, will present a company update at the Citi Global ... 2011 at 8:00 a.m. ET.   Interested parties ... via the investor section of the BioMarin website, www.BMRN.com ...
... Mich., Feb. 22, 2011 Perrigo Company (Nasdaq: ... filed an Abbreviated New Drug Application for calcipotriene 0.005% ... Taclonex® Ointment. Another generic company is the first to ... Betamethasone) ointment is indicated for the topical treatment of ...
Cached Medicine Technology:BioMarin to Present at the Citi Global Healthcare Conference 2Perrigo Confirms Filing for Generic Version of Taclonex® Ointment and Announcement of Lawsuit by Leo Pharma 2Perrigo Confirms Filing for Generic Version of Taclonex® Ointment and Announcement of Lawsuit by Leo Pharma 3
(Date:7/11/2014)... Cancer researchers in Slovenia say genetic variations ... how patients respond to treatment with pemetrexed (Alimta), the ... the full story. Click here to read the ... of Ljubljana and the Ljubljana Institute of Oncology tested ... of polymorphisms. They found that patients with genetic variations ...
(Date:7/11/2014)... 11, 2014 Anterior Cruciate Ligament (ACL) ... the type of material used to create a new ... game, say researchers presenting their work today at the ... Medicine ( AOSSM ). , “Our study ... (tissue harvested from a donor) fail more frequently than ...
(Date:7/11/2014)... Woodland Hills permanent teeth in one day ... Institute in Woodland Hills and Oxnard, Calif., will speak next ... Rey, Calif. , The award-winning prosthodontist, international speaker and ... in one day dental procedure at 1:30 p.m. Friday, July ... 15 years ago, Dr. Jivraj said. Getting new teeth in ...
(Date:7/11/2014)... 11, 2014 BellasDress, the experienced dressmaker ... popular online suppliers when it comes to beach ... new collection of beach wedding outfits in its online ... of elegant outfits. , BellasDress has been considered ... world. According to the company’s senior spokesman, BellasDress provides ...
(Date:7/11/2014)... The International Concussion Organization is ... Best Buy Theater in Times Square, New York ... growing concussion epidemic that is plaguing athletes in ... competition. , The Symposium gathers more than a ... professional athletes and legal scholars for engaging and ...
Breaking Medicine News(10 mins):Health News:New Research Finds Genetic Variables Impact Chemotherapy Response, According to Surviving Mesothelioma 2Health News:ACL Reconstructions May Last Longer With Autografts 2Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 2Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 3Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 4Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 5Health News:BellasDress Emerges As Popular Online Supplier Of 2014 Beach Wedding Dresses 2Health News:The International Concussion Organization 501(c)(3) hosts its 1st Annual Concussion Symposium at the Best Buy Theater in Time Square, NYC, July 17th, 2014. 2
... statistically significant decline in prostate specific antigen (PSA) levels, ... issue of the Journal of the National Cancer ... was associated with a reduction in prostate cancer risk. ... examined the association between statins and PSA level. ...
... PAUL, Minn., Oct. 28 Dean Barkley,candidate for US Senate ... to fight HIV/AIDS in the US and around the world., ... candidates from,Minnesota will also agree to sign the pledge," said ... "The pledge helps,voters see who is prepared to take a ...
... (Nasdaq: AHII ) announced today that the Company ... quarter ended,September 30, 2008 on Tuesday, November 4, 2008. ... same day at 10:00 a.m.,Eastern Standard Time to discuss ... access the conference call by dialing (719) 785-1758.,Participants will ...
... drug delayed disease progression, researchers found , , WEDNESDAY, Oct. ... to treat erectile dysfunction, appears effective in treating pulmonary ... high blood pressure in the arteries that supply the ... can become tired, dizzy and short of breath, because ...
... INDIANAPOLIS, Oct. 28 WellPoint, Inc. (NYSE:,WLP) announced ... at the,following conferences:, -- Oppenheimer 19th Annual ... Eastern Standard Time ("EST"); and, -- 2008 ... at,9:30 a.m. Mountain Standard Time (11:30 a.m. EST)., ...
... Corporation,(NYSE: DHR ) announced that Executive Vice ... be presenting at the Goldman Sachs Global,Industrials Conference ... 2008 at,8:00 a.m. EST. The audio will be ... Corporation is a leading manufacturer of Professional,Instrumentation, Medical ...
Cached Medicine News:Health News:Statin use associated with reduction in prostate specific antigen levels 2Health News:Senator Dean Barkley Pledges Action on HIV/AIDS Epidemic 2Health News:Cialis May Help Ease Pulmonary Hypertension 2Health News:WellPoint Announces Appearances at Upcoming Conferences 2
Supplied sterile in peel-open packages. Intended for one-time use....
... Used for catheter ... endourology procedures. Increased inner ... coils allows utilization of ... mandril while maintaining tip ...
Supplied sterile in peel-open packages. Intended for one-time use....
... access wire into the renal pelvis through a ... The mandril type shaft construction provides rigidity which ... (0.89 mm) diameter wire guide. The distal portion ... construction over the tapered mandril which provides tip ...
Medicine Products: